NCT00805870

Brief Summary

The purpose of this study is to determine the effects of fish oil supplementation (Lovaza, GlaxoSmithKline) on muscle strength, muscle soreness and inflammation following exercise.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Mar 2009

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 9, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 10, 2008

Completed
3 months until next milestone

Study Start

First participant enrolled

March 1, 2009

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2009

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2010

Completed
2.6 years until next milestone

Results Posted

Study results publicly available

September 5, 2012

Completed
Last Updated

September 5, 2012

Status Verified

August 1, 2012

Enrollment Period

9 months

First QC Date

December 9, 2008

Results QC Date

August 11, 2011

Last Update Submit

August 1, 2012

Conditions

Outcome Measures

Primary Outcomes (4)

  • Quadriceps Muscle Strength

    Quadriceps muscle strength is the maximal amount of force that the quadriceps muscles can produce during isometric knee extension exercise.

    6 days

  • Muscle Soreness of the Quadriceps Using an Algometer Strain Gauge

    The required amount of force applied to the quadriceps to elicit pain or discomfort.

    6 days

  • Creatine Kinase Activity Measured in Blood

    Creatine kinase activity is an indirect indicator of muscle damage.

    6 days

  • Interleukin-6 Measured in Blood

    Interleukin-6 is an indirect indicator of muscle inflammation.

    6 days

Study Arms (2)

Fish Oil

EXPERIMENTAL

Lovaza, 3 grams/day for 65 days

Drug: Lovaza (omega-3-acid ethyl esters)

Control

PLACEBO COMPARATOR

Wheat Germ Oil, 3 grams/day for 65 days

Drug: Wheat Germ Oil

Interventions

Lovaza, 3 grams per day for 65 days

Fish Oil

Wheat germ oil, 3 grams/day for 65 days

Control

Eligibility Criteria

Age18 Years - 30 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy, free of disease
  • Must be able to swallow capsules
  • Free of orthopedic or muscular injuries
  • Recreationally active
  • Prior consumption of fish and corn with no adverse reactions

You may not qualify if:

  • Use of non-steroidal anti-inflammatory drugs (NSAIDS) or topical analgesics during study enrollment
  • Pregnant or nursing
  • Food allergy to fish or any components of the pills which includes alpha tocopherol, partially hydrogenated vegetable oils including soybean oils and gelatin and glycerol or wheat germ oil
  • Competitive athlete or physically active more than 10 hours per week

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Western Michigan University

Kalamazoo, Michigan, 49008, United States

Location

MeSH Terms

Conditions

Myositis, Inclusion Body

Interventions

Omacorwheat germ oil

Condition Hierarchy (Ancestors)

MyositisMuscular DiseasesMusculoskeletal DiseasesNeuromuscular DiseasesNervous System Diseases

Results Point of Contact

Title
Dr. Christopher C. Cheatham
Organization
Western Michigan University

Study Officials

  • Christopher C Cheatham, Ph.D.

    Western Michigan University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chair and Associate Professor

Study Record Dates

First Submitted

December 9, 2008

First Posted

December 10, 2008

Study Start

March 1, 2009

Primary Completion

December 1, 2009

Study Completion

February 1, 2010

Last Updated

September 5, 2012

Results First Posted

September 5, 2012

Record last verified: 2012-08

Locations